PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), today announced clinical development updates on AVI-4658, AVI’s lead drug candidate for Duchenne muscular dystrophy (DMD) that is based on the company’s proprietary ESPRIT (Exon Skipping Pre-RNA Interference Technology) drug platform. AVI-4658 is designed to benefit patients with mutations in the gene for dystrophin that can be neutralized by skipping exon 51.
